HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial.
Thomas BaisEsther MeijerBart J KramersPriya VartMarc VervloetMahdi SalihBert BammensNathalie DemoulinPolina TodorovaRoman-Ulrich MüllerJan HalbritterAlexander PaliegeEmilie Cornec-Le GallBertrand KnebelmannRoser TorraAlbert C M OngFiona E Karet FranklRon T GansevoortPublished in: Trials (2024)
The HYDRO-PROTECT study will demonstrate whether co-treatment with HCT can improve the renoprotective efficacy and tolerability of tolvaptan in patients with ADPKD.
Keyphrases
- polycystic kidney disease
- randomized controlled trial
- study protocol
- end stage renal disease
- clinical trial
- chronic kidney disease
- newly diagnosed
- ejection fraction
- open label
- double blind
- prognostic factors
- peritoneal dialysis
- placebo controlled
- cell proliferation
- patient reported outcomes
- replacement therapy
- diabetic nephropathy